Dolutegravir Reported Adverse Drug Reactions: A Systematic Review Protocol

Lesley Wadesango (lwadesango@gmail.com)
Wits University: University of the Witwatersrand  https://orcid.org/0000-0002-2737-7102

Ebenezer Wiafe
Ho Teaching Hospital

Neelaveni Padayachee
Wits University: University of the Witwatersrand

Kofi Mensah
Kwame Nkrumah University of Science and Technology College of Health Sciences

Varsha Bangalee
University of KwaZulu-Natal Nelson R Mandela School of Medicine: University of KwaZulu-Natal College of Health Sciences

Protocol

Keywords: Adverse drug reactions, Antiretroviral safety, Dolutegravir, Human Immunodeficiency Virus, Pharmacovigilance

Posted Date: September 15th, 2021

DOI: https://doi.org/10.21203/rs.3.rs-882616/v1

License: © This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background: Until recently, the first-line regimen for the management of Human Immunodeficiency Virus (HIV) was Tenofovir (TDF)-Emtricitabine (FTC) and Efavirenz (EFV). However, the use of EFV has now been limited due to adverse neurosensory effects and a low genetic barrier to resistance. This regimen has been replaced by the Dolutegravir (DTG)-based regimen since DTG has a high genetic barrier to resistance. Studies have reported a higher risk of Immune Reconstitution Inflammatory Syndrome (IRIS), weight gain, insomnia, and neural tube defects amongst people who received DTG. This review aims to assess the adverse drug reaction (ADR) profile of Dolutegravir by identifying and classifying Dolutegravir-associated adverse drug reactions.

Methods: Studies will be identified from an electronic database search. Studies that are potentially eligible will be selected through screening. Two team members will independently screen all citations, full-text articles, and abstract data; conflicts will be resolved through discussion. The (PRISMA-P) flow diagram that outlines all phases of screening and reasons for exclusion will be used during the selection process. After the selection of the final study sample, a data extraction form will be used as a collection tool. The data will be entered into Cochrane Collaboration Review Manager (RevMan 5.2) for storage and management. All the evidence gathered will be assessed for bias through the use of the Risk of Bias tool RoB 2.0 of Cochrane Collaboration. Reported ADRs will then be classified. We will also provide data for the effect of different demographic factors on ADRs as well as the effects of co-administration of DTG with other drugs on ADRs. We will additionally provide information on how Dolutegravir use in different regimens affects the ADRs. Results from the review will be summarized quantitatively through meta-analysis. A forest plot will be used to present results from the meta-analysis.

Conclusion: A review of existing studies will aid in establishing the safety profile of this drug. This review will make significant contributions to healthcare practice. It will aid in improving prescribers’ and dispensers’ knowledge of the drug. Additionally, it will also aid in patient education of the potential ADRs to DTG.

Systematic review registration DOI: doi.org/10.17605/OSF.IO/Z9YAF

Background

Human Immunodeficiency Virus (HIV) remains a worldwide public health issue [2]. Although HIV management and access have been successfully implemented by the scientific community, the World Health Organization (WHO), governments, social organizations, and local societies, its global incidence was at 38 million in 2019 [2]. Globally in 2020, at least 1.5 million people were newly infected with HIV [23]. In 2020, 84% of the people living with HIV knew their status, 73% were on treatment and 66% were virally suppressed [23].

Current data suggests that 30% of all HIV infections in Southern Africa have been reported to be in South Africa [1]. The total amount of people with HIV in South Africa has since increased from 7.4 million in...
2016 to 7.7 million in 2018 [1].

Until recently, the regimen recommended for the first-line combination treatment of HIV was Tenofovir (TDF)-Emtricitabine (FTC) and Efavirenz (EFV) also known as TEE [18]. However, the consistent use of EFV due to its adverse neurosensory effects and low genetic barrier from the drug-resistance mutations has become a limitation for its use [22]. According to the latest antiretroviral therapy (ART) clinical guidelines, the Efavirenz-based regimen has been replaced by the Dolutegravir (DTG)-based regimen due to its favourable profile of maintained viral suppression and immunological recovery [25].

The recommended regimen for the primary management of HIV is Tenofovir (TDF)-Lamivudine (3TC)-Dolutegravir (DTG) also known as TLD [18]. DTG is cheap, has an increased genetic barrier to resistance, and is accessible as a fixed-combination pill, and hence was introduced as the preferred first-line therapy for HIV by the WHO in 2018 [28]. However, the administration of DTG at conception could result in neural-tube defects in infants and must therefore be used with caution in pregnant women. The drug is also known to increase the risk of insomnia and obesity [28]. There is more evidence that the risks of weight gain, insomnia, Immune Reconstitution Inflammatory Syndrome (IRIS), and neural tube defects amongst patients receiving DTG are increased [3]. These adverse drug reactions (ADRs) are common and easily identifiable. A global investigation into DTG ADRs is important in understanding how South Africa can manage a relatively new drug on the HIV regimen. These adverse effects have thus resulted in the WHO making its use conditional and recommended that DTG patients be closely monitored.

A review of the evidence from existing studies that evaluated the safety profile of DTG is relevant in promoting pharmacovigilance activities. Therefore, this proposed review aims to assess the global ADRs profile of DTG through:

1. Identification and classification of DTG-associated ADRs.
2. Establishment of the safety and efficacy of DTG in the therapy of HIV with an emphasis on pregnant women.
3. Identification and categorization of the demographic factors associated with DTG ADRs.

**Methods**

**Protocol and Registration**

The Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) guidelines were followed in the design of this review protocol. The review protocol was registered with the Open Science Framework (OSF) on the 2nd of December 2020 (doi.org/10.17605/OSF.IO/Z9YAF). If there are any protocol amendments, a description of the change and the rationale will be presented in the main review.

**Data Source and Search Strategy**
The following databases will be explored from January 2010 to date for studies: Scopus, Web of Science, PubMed, Embase, Vigiaccess, Cochrane Clinical trials registry, National institutes for health Clinical Trials Registry, and Cochrane Library.

A manual search will be also done for additional articles that may not be included on the aforementioned platforms. The following search terms will be used: “Dolutegravir”, “Antiretroviral”, “Safety”, “Adverse events”, “Human Immunodeficiency Virus”, “Adverse effects”, “Acquired Immunodeficiency Syndrome”, “Adverse drug reactions”, and “Adolescent”. These terms will be used in different combinations with boolean operators for the listed databases.

Criteria for Considering Studies for this Review

Study Designs

Studies that will be included in the review will not be limited to randomized clinical trials (RCTs), non-RCTs, cohorts, and case-controls. Systematic reviews and other forms of reviews will be excluded.

Patients (Population)

Studies that reported on DTG ADRs in males and females aged ≥ 18 years will be included. There will be no restrictions regarding ethnicity, participants’ language, country of origin, and other socio-demographics.

Interventions

We will include studies that investigated the safety of DTG either alone or in combination with other ARVs. Of particular interest is TLD, which was introduced by the WHO in 2018 as it is currently the only regimen with DTG being prescribed for first-line treatment of HIV.

Comparators

The team of reviewers will include studies that compared the DTG-containing regimens with previously recommended regimens. Of particular interest is the combination that was just downgraded: TEE.

Outcomes

Studies that reported on DTG ADR outcomes not limited to physical symptoms, hospitalizations, deterioration in organ function (hepatic or renal function), Immune Reconstitution Inflammatory Syndrome (IRIS), deaths, and the discontinuation of therapy.

The outlines outcomes will be assessed for all included studies. They will be grouped according to treatment periods. This will assist in assessing the short and long-term effects of DTG.

Exclusion Criteria

- Studies exclusively in children less than 18 years.
• Studies that were conducted in patients who were co-infected with tuberculosis and were being managed with rifampicin. This exclusion is because DTG is a substrate for Cytochrome-P450-3A4 (CYP3A4) and Uridine-diphosphate-glucuronosyltransferase-1A1 (UGT1A1). These enzymes are induced by rifampicin. The co-administration of DTG and rifampicin consequently leads to a reduction of DTG levels in the blood. Doubling the required daily dose of DTG is recommended for appropriate clinical efficacy [4]. This may affect the ADR profile of DTG.

• Studies that recruited patients with severe hepatic impairment. Hepatic toxicity has been reported without previous hepatic disease in some patients [5]. Therefore, studies conducted on these patients would potentially have biased outcomes regarding the DTG ADR profile.

• Animal studies will be excluded because the reviewers are interested in clinically relevant study findings regarding DTG ADRs.

• Studies that were not reported in the English language.

Selection of Studies

Two reviewers/authors will identify studies from the electronic database search and evaluate their eligibility for inclusion in the review. The potentially eligible studies will be identified through the screening of titles and abstracts after duplicated studies have been identified and removed. Another set of two reviewers will independently perform full-text screening and data extraction. Any disagreements that may arise between the reviewers, during the titles and abstracts screening, and the full-text screening, will be resolved through a discussion with a third reviewer. The agreement between each reviewer pair will be measured and reported by Kappa statistics. A PRISMA flow diagram illustrating the various stages of the review, and results obtained will be presented.

Data Extraction and Management

After the selection of the final study sample, a data extraction form (see additional file 1) will be used to extract data. The form will contain the following sections:

• Table 1: Study Characteristics - Lead author, year, study design, sample size, study setting/country, details of DTG/antiretroviral drug regimen/combination/intervention, duration of treatment, comparator, and funding source.

• Table 2: Summary of Findings - Outcomes (any adverse drug reactions/events, most common ADRs/events, ADRs/events requiring discontinuation, number of ADRs/adverse events leading to death).

The data extraction form will be tested to determine its validity and reliability. In the event of unclear or missing information in the selected studies, the corresponding authors of those studies will be contacted via email for clarification and to provide adequate information. Two independent reviewers will screen the contents of the data extraction form to check for the accuracy and completeness of data. Any observed differences will be resolved by discussion.
Quality assessment and risk of bias

To assess the risk of bias for randomized control studies, the Cochrane Risk of Bias tool will be used. The tool offers a basis for assessing the risk of bias in the outcomes of any randomized trial [27]. Assessment is arranged into several domains that bias may be introduced [27]. A judgement/conclusion of a high risk of bias in any domain consequently means the whole study has a high risk of bias [27].

The Newcastle-Ottawa Scale will be used to assess the risk of bias for nonrandomized studies. Each study will be judged on eight items, categorized into three groups: the selection of the study groups, the comparability of the groups, and the determination of the exposure or outcome of interest for case-control or cohort studies [26]. A study can be awarded a maximum of one star for each numbered item within the selection and outcome categories and a maximum of two stars can be given for Comparability [26].

Two reviewers will independently assess the methodological quality of eligible studies and avoid the exclusion of studies based on the methodological quality assessment outcomes. For studies that employed other study designs, the reviewers would adopt an appropriate methodological quality appraisal tool. A third reviewer would serve as an arbiter in instances of disagreement between the independent reviewers.

Data Synthesis

Adverse drug reactions will be classified into six types. Dose-related reactions (ARRs at normal or overdose), non-dose-related reactions (eg allergy or anaphylaxis), dose and time-related (due to dose accumulation), time-related (due to prolonged use), withdrawal (effects after stopping the drug), and failure of therapy [6].

We will further group reported ADRs as:

- The patient/participant was hospitalized due to the reaction.
- The patient/participant’s life was threatened by the reaction.
- The patient/participant’s hospitalization time was prolonged due to the reaction.
- The reaction caused long-term patient/participant disability.
- The reaction did not lead to any of the above but was severe.
- The reaction was not severe.

The sociodemographic data of participants of included studies will be synthesized and presented as part of the study findings. Also, findings on the co-administration of DTG with other drugs, and how DTG use in different regimens affects adverse drug reactions will be presented. The findings from the review will be summarized quantitatively, unless otherwise. Homogenous studies will be analysed statistically through a meta-analysis. The lead author will make the entry into Cochrane Collaboration Review
Manager (RevMan 5.2), and the second author will check for data entry errors and manage them appropriately.

Results from the meta-analysis will be presented in a forest plot. Where possible, a sensitivity and sub-group analysis will be performed.

**Discussion And Conclusions**

Globally, more than 38 million people are infected by HIV. Effective antiretroviral therapy with the DTG regimen is available, yet there are safety concerns about the risks of weight gain, insomnia, Immune Reconstitution Inflammatory Syndrome (IRIS), and neural tube defects.

Our findings regarding the overall safety of DTG will be of great significance to policy-makers, healthcare providers, and patients. Additionally, we hope to identify gaps in research that may form the basis for future studies of DTG in ART regimens. The results of this study will provide a basis for ongoing medication safety monitoring for Dolutegravir regimens.

**Limitations of the review**

The reporting quality of some studies may be poor thus affecting the results. Studies may fail to provide a clear definition of ADRs or report on ADR incidence data. Additionally, studies might not use the same classification when reporting ADRs. This might make it difficult to draw an accurate conclusion.

**Abbreviations**

3TC: Lamivudine; ADR: Adverse drug reaction; ART: Antiretroviral therapy; CYP3A4: Cytochrome-P450-3A4; DTG: Dolutegravir; EFV: Efavirenz; FTC: Emtricitabine; HIV: Human Immunodeficiency Virus; IRIS: Immune Reconstitution Inflammatory Syndrome; OSF: Open Science Framework; PRISMA-P: The Preferred Reporting Items for Systematic Reviews and Meta-Analysis Protocol; RCTs: Randomized clinical trials; TDF: Tenofovir; UGT1A1: Uridine-diphosphate-glucuronosyltransferase-1A1; WHO: World Health Organization

**Declarations**

**Ethics approval and consent to participate**

None.

**Consent for publication**

None.

**Availability of data and materials**
None.

Competing interests

None.

Funding

None.

Authors’ contributions

All the authors contributed significantly to the conception and development of the manuscript. The listed authors have read the manuscript for scientific content and have approved the manuscript for publication.

Acknowledgment

The authors acknowledge the Department of Pharmacy and Pharmacology, Faculty of Health Sciences at the University of the Witwatersrand.

References

1. AVERT. (2015). HIV and AIDS in South Africa. [online] Available at: https://www.avert.org/professionals/hiv-around-world/sub-saharan-africa/south-africa#:%7E:text=South%20Africa%20has%20the%20biggest (Accessed: 12 Aug. 2020).

2. AVERT. (2018). Global HIV and AIDS Statistics. [online] Available at: https://www.avert.org/global-hiv-and-aids-statistics (Accessed: 20 Aug 2020).

3. Batista, C.J.B., Correa, R.G., Evangelista, L.R., Fleck, K., Silva, L., Renaud, F., Vitoria, M., Doherty, M. and Benzaken, A.S. (2019). The Brazilian Experience of Implementing the Active Pharmacovigilance of Dolutegravir. Medicine, 98(10): 1-148.

4. Cevik, M. and McGann, H., 2018. Dolutegravir use in combination with rifampicin-based tuberculosis therapy: 3 years of real-world experience in a large UK teaching hospital. Sexually transmitted infections, 94(6), pp.420-420.

5. Cunha, J.P. (2020). Dolutegravir: Side Effects, Dosages, Treatment, Interactions, Warnings. Available at: https://www.rxlist.com/consumer_tivicay_dolutegravir/drugs-condition.htm (Accessed: 22 Feb 2021).

6. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000 Oct 7;356(9237):1255-9. doi: 10.1016/S0140-6736(00)02799-9. PMID: 11072960.

7. Golafshani, N. (2003). Understanding Reliability and Validity in Qualitative Research. The Qualitative Report, 8(4): 597–606.
8. Havlir, D.V. and Doherty, M.C. (2019). Global HIV Treatment — Turning Headwinds to Tailwinds. *New England Journal of Medicine*, 381(9): 873–874.

9. Hoffmann, C., Welz, T., Sabranski, M., Kolb, M., Wolf, E., Stellbrink, H.-J. and Wyen, C. (2016). Higher Rates of Neuropsychiatric Adverse Events leading to Dolutegravir Discontinuation in Women and Older Patients. *HIV Medicine*, 18(1): 56–63.

10. Kandel, C. and Walmsley, S. (2015). Dolutegravir – A Review of the Pharmacology, Efficacy, and Safety in the Treatment of HIV. Drug Design, Development and Therapy, [online] p.3547. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4500604/ (Accessed 20 Jun. 2020).

11. Kanters, S., Vitoria, M., Doherty, M., Socías, M.E., Ford, N., Forrest, J.I., Popoff, E., Bansback, N., Nsanzimana, S., Thorlund, K. and Mills, E.J. (2016). Comparative Efficacy and Safety of First-line Antiretroviral Therapy for the Treatment of HIV infection: A Systematic Review and Network Meta-analysis. The Lancet HIV, 3(11): 510–520.

12. Liberati, A., Altman, D.G., Tetzlaff, J., Mulrow, C. and Götzsche P.C. (2009) The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration. PLoS Med 6(7): e1000100. doi:10.1371/journal.pmed.1000100.

13. Llibre, J.M., Pulido, F., García, F., Garcia Deltoro, M., Blanco, J.L. and Delgado, R. (2015). Genetic Barrier to Resistance for Dolutegravir. *AIDS Rev*, 17(1): 56-64.

14. Min, S., Sloan, L., DeJesus, E., Hawkins, T., McCurdy, L., Song, I., Stroder, R., Chen, S., Underwood, M., Fujiwara, T., Piscitelli, S. and Lalezari, J. (2011). Antiviral Activity, Safety, and Pharmacokinetics/pharmacodynamics of dolutegravir as 10-day Monotherapy in HIV-1-infected Adults. *AIDS*, 25(14): 1737–1745.

15. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. *PLoS Med*, 6(7): e1000097. doi:10.1371/journal.pmed.1000097.

16. Pannucci, C.J. and Wilkins, E.G. (2010). Identifying and Avoiding Bias in Research. Plastic and Reconstructive Surgery, 126(2): 619–625.

17. Phillips, K.D., Harris, R.F. and Haddad, L.M. (2019). Human Immunodeficiency Virus/AIDS. Handbook of Sleep Disorders in Medical Conditions, pp.293–307.

18. Republic of South Africa National Department of Health (2019). ART Clinical Guidelines for the Management of HIV in Adults, Pregnancy, Adolescents, Children, Infants and Neonates. Available at: http://www.health.gov.za/9 (Accessed 10 Aug. 2020).

19. Rutherford, G.W. and Horvath, H. (2016). Dolutegravir Plus Two Nucleoside Reverse Transcriptase Inhibitors versus Efavirenz Plus Two Nucleoside Reverse Transcriptase Inhibitors As Initial Antiretroviral Therapy for People with HIV: A Systematic Review. *PLOS ONE*, 11(10), p.e0162775.

20. Snedecor, S.J., Radford, M., Kratochvil, D., Grove, R. and Punekar, Y.S. (2019). Comparative Efficacy and Safety of Dolutegravir Relative to Common Core Agents in Treatment-naïve Patients Infected with HIV-1: A Systematic Review and Network Meta-analysis. *BMC Infectious Diseases*, 19(1).
21. The Health Foundation (2010). Identify Innovate Demonstrate Encourage Global Trigger Tools Evidence Scan.

22. The NAMSAL ANRS 12313 Study Group. Dolutegravir-based or low-dose efavirenz–based regimen for the treatment of HIV-1. N Engl J Med 2019;381:816-26. DOI: 10.1056/NEJMoa1904340

23. UNAIDS. 2021. Global HIV & AIDS statistics — Fact sheet. Available: https://www.unaids.org/en/resources/fact-sheet (Accessed 7 July 2021).

24. Venter, W.D.F., Moorhouse, M., Sokhela, S., Fairlie, L., Mashabane, N., Masenya, M., Serenata, C., Akpomiemie, G., Qavi, A., Chandiwana, N., Norris, S., Chersich, M., Clayden, P., Abrams, E., Arulappan, N., Vos, A., McCann, K., Simmons, B. and Hill, A. (2019). Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV. New England Journal of Medicine, 381(9): 803–815.

25. Walmsley, S.L., Antela, A., Clumeck, N., Duiculescu, D., Eberhard, A., Gutiérrez, F., Hocqueloux, L., Maggiolo, F., Sandkovsky, U., Granier, C., Pappa, K., Wynne, B., Min, S. and Nichols, G. (2013). Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection. New England Journal of Medicine, 369(19): 1807–1818.

26. Wells, G., Shea, B., O’Connell, D., Peterson, J., Welch, V., Losos, M. and Tugwell, P, 2014. Newcastle-Ottawa quality assessment scale cohort studies. University of Ottawa.

27. Whiting, P., Savović, J., Higgins, J. P., Caldwell, D. M., Reeves, B. C., Shea, B., Davies, P., Kleijnen, J., Churchill, R., & ROBIS group (2016). ROBIS: A new tool to assess risk of bias in systematic reviews was developed. Journal of clinical epidemiology, 69, 225–234. https://doi.org/10.1016/j.jclinepi.2015.06.005.

28. World Health Organization (2018). WHO Implementation Tool for Monitoring the Toxicity of New Antiretroviral and Antiviral Medicines in HIV and Viral Hepatitis Programmes.

29. World Health Organization (2019). Update of Recommendations on First-and Second-Line Antiretroviral Regimens Policy Brief HIV Treatment.

30. World Health Organization. (2009). A Practical Handbook on the Pharmacovigilance of Antiretroviral Medicines. Geneva.

31. Yadav, G., Kumar, P., Kumar, Y. and Singh, P.K. (2018). Dolutegravir, Second Generation Integrase Inhibitor: A New Hope for HIV Patient. European Journal of Molecular and Clinical Medicine, 5(1): 20–29.

32. Zash, R., Makhema, J. and Shapiro, R.L. (2018). Neural-Tube Defects with Dolutegravir Treatment from the Time of Conception. New England Journal of Medicine, 379(10): 979–981.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- PRISMA2020checklist.pdf
- additionalfile1dataextractiontables.docx